SLTM

Across TCGA pan-cancer cohorts, SLTM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLTM data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SLTM mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLTM expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, HNSC, and PDAC are the cancer types where SLTM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.659	0.311	.007	14	view →
HNSC	DFS	Quartile	III,IV	0.673	0.917	.014	13	view →
PDAC	OS	Quartile	All	0.401	0.606	.011	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLTM–GBM (OS)

Open the GBM breakdown →